Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller
Some HIV-1–infected patients develop broad and potent HIV-1 neutralizing antibodies
(bNAbs) that when passively transferred to mice or macaques can treat or prevent infection …
(bNAbs) that when passively transferred to mice or macaques can treat or prevent infection …
Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design
Broadly neutralizing antibodies (bNAbs) against HIV-1 Env V1V2 arise in multiple donors.
However, atomic-level interactions had previously been determined only with antibodies …
However, atomic-level interactions had previously been determined only with antibodies …
High-throughput identification of prefusion-stabilizing mutations in SARS-CoV-2 spike
Designing prefusion-stabilized SARS-CoV-2 spike is critical for the effectiveness of COVID-
19 vaccines. All COVID-19 vaccines in the US encode spike with K986P/V987P mutations to …
19 vaccines. All COVID-19 vaccines in the US encode spike with K986P/V987P mutations to …
Structure-based design of prefusion-stabilized human metapneumovirus fusion proteins
The human metapneumovirus (hMPV) fusion (F) protein is essential for viral entry and is a
key target of neutralizing antibodies and vaccine development. The prefusion conformation …
key target of neutralizing antibodies and vaccine development. The prefusion conformation …
HIV-1 Env trimer opens through an asymmetric intermediate in which individual protomers adopt distinct conformations
HIV-1 entry into cells requires binding of the viral envelope glycoprotein (Env) to receptor
CD4 and coreceptor. Imaging of individual Env molecules on native virions shows Env …
CD4 and coreceptor. Imaging of individual Env molecules on native virions shows Env …
Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike
L Scharf, JF Scheid, JH Lee, AP West, C Chen, H Gao… - Cell reports, 2014 - cell.com
Broadly neutralizing antibodies (bNAbs) to HIV-1 envelope glycoprotein (Env) can prevent
infection in animal models. Characterized bNAb targets, although key to vaccine and …
infection in animal models. Characterized bNAb targets, although key to vaccine and …
Intermediate conformations of CD4-bound HIV-1 Env heterotrimers
Abstract HIV-1 envelope (Env) exhibits distinct conformational changes in response to host
receptor (CD4) engagement. Env, a trimer of gp120 and gp41 heterodimers, has been …
receptor (CD4) engagement. Env, a trimer of gp120 and gp41 heterodimers, has been …
Improving the immunogenicity of native-like HIV-1 envelope trimers by hyperstabilization
The production of native-like recombinant versions of the HIV-1 envelope glycoprotein (Env)
trimer requires overcoming the natural flexibility and instability of the complex. The …
trimer requires overcoming the natural flexibility and instability of the complex. The …
Infectious RNA: human immunodeficiency virus (HIV) biology, therapeutic intervention, and the quest for a vaccine
Y van Heuvel, S Schatz, JF Rosengarten, J Stitz - Toxins, 2022 - mdpi.com
Different mechanisms mediate the toxicity of RNA. Genomic retroviral mRNA hijacks infected
host cell factors to enable virus replication. The viral genomic RNA of the human …
host cell factors to enable virus replication. The viral genomic RNA of the human …
Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding
Elicitation of broadly neutralizing antibodies (bnAbs) is a primary HIV vaccine goal. Native-
like trimers mimicking virion-associated spikes present nearly all bnAb epitopes and are …
like trimers mimicking virion-associated spikes present nearly all bnAb epitopes and are …